EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer.

Jang A, Fowler P, Helminiak K, Kumar HLS, Pasucal J, Delong V, Zhong JY, Jindal T, Grier AL, Patel RR, Hislop M, Cesano A, Villaluna K, Younginger B, Wolff K, Richey K, Bray J, Garcia H, Adamowicz T, Reese A, Nizam A, Gupta S, Wee CE, Margevicius S, Fu P, Mendiratta P, Sheng IY, Brown JR, Garcia JA, Barata PC

Open source

DOI: 10.1093/oncolo/oyaf434
Published: 2026 Jan 17
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyaf434,
  title = {EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer.},
  author = {Jang A and Fowler P and Helminiak K and Kumar HLS and Pasucal J and Delong V and Zhong JY and Jindal T and Grier AL and Patel RR and Hislop M and Cesano A and Villaluna K and Younginger B and Wolff K and Richey K and Bray J and Garcia H and Adamowicz T and Reese A and Nizam A and Gupta S and Wee CE and Margevicius S and Fu P and Mendiratta P and Sheng IY and Brown JR and Garcia JA and Barata PC},
  year = {2026},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyaf434},
  url = {https://doi.org/10.1093/oncolo/oyaf434}
}

RIS

TY  - JOUR
TI  - EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer.
AU  - Jang A
AU  - Fowler P
AU  - Helminiak K
AU  - Kumar HLS
AU  - Pasucal J
AU  - Delong V
AU  - Zhong JY
AU  - Jindal T
AU  - Grier AL
AU  - Patel RR
AU  - Hislop M
AU  - Cesano A
AU  - Villaluna K
AU  - Younginger B
AU  - Wolff K
AU  - Richey K
AU  - Bray J
AU  - Garcia H
AU  - Adamowicz T
AU  - Reese A
AU  - Nizam A
AU  - Gupta S
AU  - Wee CE
AU  - Margevicius S
AU  - Fu P
AU  - Mendiratta P
AU  - Sheng IY
AU  - Brown JR
AU  - Garcia JA
AU  - Barata PC
PY  - 2026
JO  - The oncologist
DO  - 10.1093/oncolo/oyaf434
UR  - https://doi.org/10.1093/oncolo/oyaf434
ER  -

APA

A, J., P, F., K, H., HLS, K., J, P., V, D., JY, Z., T, J., AL, G., RR, P., M, H., A, C., K, V., B, Y., K, W., K, R., J, B., H, G., T, A., A, R., A, N., S, G., CE, W., S, M., P, F., P, M., IY, S., JR, B., JA, G., & PC, B. (2026). EXTRA-PC: a phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer.. The oncologist. https://doi.org/10.1093/oncolo/oyaf434

Source records

pubmed · retrieved 2026-09-25T20:16:29.969Z